The AMA & BIA 2026 Asian Light Medical Aesthetics Industry Conference and the 3rd Injectable Medical Aesthetics Summit focuses on five major areas: injectable R&D, regenerative materials, full-link quality control, skin regeneration mechanism, and optoelectronics and digital therapeutics. Through the dual engine of "breaking the wall of technology and building the foundation of quality control", the conference will bring together top experts and industry leaders in the Asia-Pacific region to promote the collaboration between industry, academia, research and application, reshape the new ecology of Asia's light medical aesthetic industry, and jointly witness and promote the prosperity and development of China's medical aesthetic device industry with a 2-day agenda, 7 theme sections and 3 salons.

On January 8, 2026, the National Medical Products Administration (NMPA) released the delivery information of medical device approval certificates, and the "sodium hyaluronate solution for injection" independently developed by Hangzhou Concord Medical Products Co., Ltd. (hereinafter referred to as "Hangzhou Concord Medical") was officially approved for marketing (registration certificate number: National Machinery Injection Approval 20263130004, approval date: January 7, 2026). Guangzhou Jiutai Pharmaceutical and Equipment Technology Co., Ltd. (hereinafter referred to as "Jiutai Pharmaceutical Equipment") provides professional medical services for this product, helping the product to efficiently pass the review and approval, and jointly promoting the smooth implementation of this new product in the field of medical aesthetics。

On January 9, 2026, the launch conference of the "Blue Book of Medical Devices: Development Report of China's Medical Device Industry (2025)" was held. As the ninth authoritative report on the medical device industry carefully compiled since 2017, this book is organized and compiled by the China Drug Administration Research Association and published by the Social Science Literature Press, which embodies the wisdom crystallization of more than 30 editorial board members and nearly 100 authors, continues the core characteristics of the Blue Book, and provides a very valuable reference for the development of the medical device industry.